文献速递白血病

序贯大剂量阿糖胞苷联合米托蒽醌(S-HAM)方案对比标准双诱导方案治疗急性髓系白血病:一项3期研究

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
PubMed 文献 · Leukemia · 2018-10-01

该3期研究将初诊成人急性髓系白血病患者按1:1随机分配至S-HAM剂量密集诱导组(203例)或标准双诱导组(184例)。S-HAM组总缓解率为77%,标准双诱导组为72%,差异无统计学意义(P=0.202);中位总生存期分别为35个月和25个月(P=0.323)。S-HAM组关键性白细胞减少持续时间及住院时间均显著缩短。

要点

  • S-HAM组总缓解率为77%,标准双诱导组为72%,差异无统计学意义(P=0.202)。
  • S-HAM组中位总生存期为35个月,标准双诱导组为25个月(P=0.323)。
  • S-HAM组关键性白细胞减少中位持续时间29天,标准双诱导组44天(P<0.001)。

核心结论

  • S-HAM剂量密集诱导方案相比标准双诱导方案在总缓解率和总生存期上呈现有利趋势但无显著差异。
  • S-HAM方案使关键性白细胞减少持续时间及住院时间显著缩短约2周。

研究设计与样本

  • 3期随机对照研究,初诊成人急性髓系白血病患者中央随机1:1分配至S-HAM组(203例)或标准双诱导组(184例),共387例可评估。
  • S-HAM组第2周期化疗于第8天开始(剂量密集),标准双诱导组采用TAD-HAM或HAM(-HAM)方案,第2周期于第21天开始。

主要发现

  • 总缓解率(完全缓解+不完全缓解)S-HAM组77% vs 标准双诱导组72%,差异无统计学意义(P=0.202)。
  • 中位总生存期S-HAM组35个月 vs 标准双诱导组25个月(P=0.323)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 = "dose-dense") and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 = "standard"). 387 evaluable patients were randomly assigned to S-HAM (N = 203) and to standard double induction (N = 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CRi) was not significantly different (P = 0.202) between S-HAM (77%) and double induction (72%). The median overall survival was 35 months after S-HAM and 25 months after double induction (P = 0.323). Duration of critical leukopenia was significantly reduced after S-HAM (median 29 days) versus double induction (median 44 days)-P < 0.001. This translated into a significantly shortened duration of hospitalization after S-HAM (median 37 days) as compared to standard induction (median 49 days)-P < 0.001. In conclusion, dose-dense induction therapy with the S-HAM regimen shows favorable trends but no significant differences in ORR and OS compared to standard double induction. S-HAM significantly shortens critical leukopenia and the duration of hospitalization by 2 weeks.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Braess J, Amler S, Kreuzer KA, et al. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. Leukemia. 2018. PMID: 30275528. doi:10.1038/s41375-018-0268-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。